Key result
Oral rotavirus vaccines cut rotavirus hospitalizations and ED visits by ~50% in high child-mortality countries.
Why the study?
Despite the effectiveness of oral rotavirus vaccines in low- to middle-income countries, numerous factors hinder optimal performance and evaluation, prompting an update on vaccine response factors and next-generation candidates.
What are the factors affecting oral rotavirus vaccine performance in low- to middle-income countries and what is the status of next-generation vaccines?
What are the factors affecting oral rotavirus vaccine performance in low- to middle-income countries and what is the status of next-generation vaccines?
Closing the gap in rotavirus prevention between LMICs and high-income countries requires addressing biological and methodological challenges and evaluating next-generation vaccines.
Supports rotavirus vaccination in high-mortality settings; leaves open optimization of performance gaps and next-generation vaccine evaluation in LMICs.
In the decade since oral rotavirus vaccines (ORV) were recommended by the World Health Organization for universal inclusion in all national immunization programs, significant yet incomplete progress has been made toward reducing the burden of rotavirus in low- to middle-income countries (LMIC). ORVs continue to demonstrate effectiveness and impact in LMIC, yet numerous factors hinder optimal performance and evaluation of these vaccines. This review will provide an update on ORV performance in LMIC, the increasing body of literature regarding factors that affect ORV response, and the status of newer and next-generation rotavirus vaccines as of early 2020. Fully closing the gap in rotavirus prevention between LMIC and high-income countries will likely require a multifaceted approach accounting for biological and methodological challenges and evaluation and roll-out of newer and next-generation vaccines.
No takes yet. Share an insight, caveat, or question.
Benjamin Lee (2020) conducted a review in Rotavirus gastroenteritis. Oral rotavirus vaccines was evaluated. Oral rotavirus vaccines reduced rotavirus hospitalizations or emergency department visits by a median of 50% in children under 5 years in high child-mortality countries, despite underperforming compared to high-income settings.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: